跳到正文
原文
STAT Pharma 医药频道· Ed Silverman·· 22 天前AI 评分15

STAT Pharmalittle:美国劳工部新规要求 PBM 披露药价与药企返点,财政部拟限制对华生物科技投资

STAT+: Pharmalittle: We’re reading about a new policy for compounding peptides, a PBM disclosure rule, and more

AI 导读

美国劳工部预计周四发布新规,要求药品福利管理机构(PBM)向自保雇主客户披露其药品采购价格及从药企获得的返点等报酬细节,新规将于7月生效。规则还要求披露可能引导患者转向特定药品的各类付款。此前美国财政部提议限制美国对中国生物科技产业的投资,业界就该提案的实际影响仍存分歧。

正文

Hello, everyone, and welcome to the middle of the week. Congratulations on making it this far. It is an accomplishment, after all. The next step is to … keep going. And why not? Just consider the alternatives. On that optimistic note, please join us for a needed cup or three of stimulation. Our choice today is coconut rum. Meanwhile, here are some items of interest to get you going. Have a wonderful day and do drop us a line when you hear something juicy. …

Ever since the U.S. Department of Treasury proposed to limit U.S. investment in the Chinese biotech industry last week, players across the U.S. are arguing over the significance of the restrictions, STAT explains. The main debate to date had been over whether restrictions are needed. Is it better to play offense by boosting domestic R&D or to play defense by trying to prevent Chinese biotechs from catching up? Is it even possible to slow China’s advance? Now, the debate has turned to the impact of the proposed rule, which is more aggressive than some anticipated. A Treasury official said licensing deals are exempt, but that exemption is at the heart of disagreements over the effects of the proposal.

The Trump administration will require pharmacy benefit managers to disclose details on how they get paid as part of an accelerating push to overhaul the industry, The Wall Street Journal reports. Under a new regulation the U.S. Department of Labor expects to release on Thursday, PBMs will have to provide clients with granular information about prices they pay for medicines, as well as payments they receive from drugmakers. The new regulation, which will take effect in July and apply to self-insured employers, will require PBMs to disclose rebates and other types of payment from drugmakers, including any that might lead patients to be steered to certain drugs over others.

Continue to STAT+ to read the full story…

来源:STAT Pharma 医药频道 · statnews.com